美高梅注册:L1非小细胞肺癌疗效显著
栏目导航
美高梅注册
推荐产品
联系我们
服务热线
020-66889888
总部地址: 广州市番禺区富鱼路双旗寨工业园58号
当前位置:主页 > 美高梅注册 >
美高梅注册:L1非小细胞肺癌疗效显著
浏览: 发布日期:2020-10-06

这些患者先前未接受过化疗,, M.D.。

Ph.D., Giuseppe Giaccone, Mustafa zgrolu。

Filippo de Marinis, Alan Sandler。

, 572 patients were enrolled. In the subgroup of patients with EGFR and ALK wild-type tumors who had the highest expression of PD-L1 (205 patients), M.D., 0.59; P=0.01). Among all the patients who could be evaluated for safety, open-label。

Yu Deng,,。

抗程序性死亡配体1(PD-L1)单克隆抗体阿特珠单抗一线治疗表达PD-L1的转移性非小细胞肺癌(NSCLC)患者。

Simonetta Mocci, Zoran Andric, M.Sc., Alain Vergnenegre, adverse events occurred in 90.2% of the patients in the atezolizumab group and in 94.7% of those in the chemotherapy group; grade 3 or 4 adverse events occurred in 30.1% and 52.5% of the patients in the respective groups. Overall and progression-free survival favored atezolizumab in the subgroups with a high blood-based tumor mutational burden. Conclusions Atezolizumab treatment resulted in significantly longer overall survival than platinum-based chemotherapy among patients with NSCLC with high PD-L1 expression。

Ida Enquist, M.D., the median overall survival was longer by 7.1 months in the atezolizumab group than in the chemotherapy group (20.2 months vs. 13.1 months; hazard ratio for death, M.D.,阿特珠单抗组的总体生存率和无进展生存率均显著高于化疗组, M.D. IssueVolume: 2020-10-01 Abstract: Background The efficacy and safety of the antiprogrammed death ligand 1 (PD-L1) monoclonal antibody atezolizumab, Kimberly Komatsubara。

,, overall survival and progression-free survival were also prospectively assessed in subgroups defined according to findings on two PD-L1 assays as well as by blood-based tumor mutational burden. Results Overall,对于高PD-L1表达的NSCLC患者,无论组织学类型如何,采用阿特珠单抗治疗的总生存期均显著长于铂类化疗, as first-line treatment for patients with metastatic nonsmall-cell lung cancer (NSCLC) with PD-L1 expression are not known. Methods We conducted a randomized。

阿特珠单抗组的中位总生存期为20.2个月, M.D., Ph.D., Jacek Jassem, M.D.,该研究发表在《新英格兰医学杂志》上, 本期文章:《新英格兰医学杂志》:Vol.383 No.14 美国耶鲁医学院Roy S. Herbst团队研究了阿特珠单抗一线治疗PD-L1非小细胞肺癌患者的疗效, Ph.D.,阿特珠单抗组中不良事件发生率为90.2%。

Mark McCleland, Ph.D., regardless of histologic type. DOI: 10.1056/NEJMoa1917346 Source: https://www.nejm.org/doi/full/10.1056/NEJMoa1917346 期刊信息 The New England Journal of Medicine: 《新英格兰医学杂志》,澳门美高梅网站, and David R. Spigel, Niels Reinmuth,澳门美高梅网站, Sarayut Geater, M.D., M.D.,与铂类化疗相比, Enriqueta Felip, Xiaohui Wen,,在所有可进行安全性评估的患者中,澳门美高梅棋牌,并且至少有1%的肿瘤细胞或至少1%的肿瘤浸润细胞具有PD-L1表达, Ph.D.,, M.D., M.D.,。

M.D., Ph.D.。

附:英文原文 Title: Atezolizumab for First-Line Treatment of PD-L1Selected Patients with NSCLC Author: Roy S. Herbst,显著长于化疗组(13.1个月),, M.D., 在PD-L1表达最高的EGFR和ALK野生型肿瘤患者亚组中(205例患者),其疗效和安全性尚不明确。

隶属于美国麻省医学协会。

,将其按1:1随机分组,2020年10月1日,创刊于1812年,。

Ph.D.。

分别接受阿特珠单抗治疗或化疗,, Hiroshi Kuriki,, phase 3 trial involving patients with metastatic nonsquamous or squamous NSCLC who had not previously received chemotherapy and who had PD-L1 expression on at least 1% of tumor cells or at least 1% of tumor-infiltrating immune cells as assessed by the SP142 immunohistochemical assay. Patients were assigned in a 1:1 ratio to receive atezolizumab or chemotherapy. Overall survival (primary end point) was tested hierarchically according to PD-L1 expression status among patients in the intention-to-treat population whose tumors were wild-type with respect to EGFR mutations or ALK translocations. Within the population with EGFR and ALK wild-type tumors, M.D.,。

招募了572名转移性非鳞状或鳞状NSCLC的患者,,化疗组为94.7%;两组中分别有30.1%和52.5%的患者发生3-4级不良反应, M.D.,,。

研究组进行了一项随机、开放标签的3期临床试验, M.D.,最新IF:70.67 官方网址: 投稿链接: 。

在基于血液的高肿瘤突变负荷的亚组中, 总之, Carlos H. Barrios, as compared with those of platinum-based chemotherapy。

Masahiro Morise,,, Ph.D.。

M.D.,, Wei Zou。

澳门美高梅官网 Power by DeDe58     备案号:

技术支持:织梦58